Search
Research
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)Pneumococcal disease (PD) remains a major health concern with considerable morbidity and mortality in children. Currently licensed pneumococcal conjugate vaccines (PCVs) confer protection against PD caused by most vaccine serotypes, but non-vaccine serotypes contribute to residual disease. V114 is a 15-valent PCV containing all 13 serotypes in Prevnar 13™ (PCV13) and additional serotypes 22F and 33F. This pivotal phase 3 study compared safety and immunogenicity of V114 and PCV13.
Research
Assessing the protective effect of influenza vaccine against laboratory confirmed influenza in hospitalised children aged 6-59 monthsInfluenza vaccine was offered to all children aged 6-59 months resident in Western Australia in 2008, and we wished to evaluate the effectiveness of this immunisation programme.
Research
Vaccine Effectiveness Against Laboratory-confirmed Influenza in Healthy Young Children A Case-Control StudyThe Western Australian Influenza Vaccine Effectiveness study commenced in 2008 to evaluate a new program to provide free influenza vaccine to all children...
Research
Detection of the rapid emergency of the H274 mutation associated with oseltamivir-resistanceIn 2009 a new swine-origin influenza virus A/H1N1 (A/H1N1 09) emerged, causing the century's first pandemic.
Research
Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised studyWe evaluated the immunogenicity and safety of 1 and 2 doses of MenACWY-TT, given alone or co-administered with PCV13 in toddlers.
Research
Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patientsAll children who are receiving therapy for cancer should receive a single dose of PCV13 as soon as possible after diagnosis, regardless of prior PCV exposure.
Research
Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in AustraliaTo evaluate the effect on safety and coverage of earlier (18 m) scheduling of MMRV vaccine as the second dose of measles-containing vaccine in Australia.
Research
A prospective cohort study assessing the reactogenicity of pertussis and influenza vaccines administered during pregnancyData on systemic and local reactions following receipt of TIV and dTpa during pregnancy support the safety of antenatal vaccination
Research
Five-Year Antibody Persistence And Safety Following a Combined Haemophilus Influenzae Neisseria Meningitidis Tetanus Toxoid VaccinesThe purpose of this article is to investigate whether the number and timing of stressors experienced during pregnancy impacted longterm motor development at...
Research
Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: A randomised studyThis trial tested the safety & consistency of the immune responses elicited by three consecutive lots of tetravalent dengue vaccine.